<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Crossen J</submitter><funding>NHLBI NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIH</funding><pagination>697-712</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9989883</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>122(4)</volume><pubmed_abstract>During clotting under flow, thrombin rapidly generates fibrin, whereas fibrin potently sequesters thrombin. This co-regulation was studied using microfluidic whole blood clotting on collagen/tissue factor, followed by buffer wash, and a start/stop cycling flow assay using the thrombin fluorogenic substrate, Boc-Val-Pro-Arg-AMC. After 3 min of clotting (100 s&lt;sup>-1&lt;/sup>) and 5 min of buffer wash, non-elutable thrombin activity was easily detected during cycles of flow cessation. Non-elutable thrombin was similarly detected in plasma clots or arterial whole blood clots (1000 s&lt;sup>-1&lt;/sup>). This thrombin activity was ablated by Phe-Pro-Arg-chloromethylketone (PPACK), apixaban, or Gly-Pro-Arg-Pro to inhibit fibrin. Reaction-diffusion simulations predicted 108 nM thrombin within the clot. Heparin addition to the start/stop assay had little effect on fibrin-bound thrombin, whereas addition of heparin-antithrombin (AT) required over 6 min to inhibit the thrombin, indicating a substantial diffusion limitation. In contrast, heparin-AT rapidly inhibited thrombin within microfluidic plasma clots, indicating marked differences in fibrin structure and functionality between plasma clots and whole blood clots. Addition of GPVI-Fab to blood before venous or arterial clotting (200 or 1000 s&lt;sup>-1&lt;/sup>) markedly reduced fibrin-bound thrombin, whereas GPVI-Fab addition after 90 s of clotting had no effect. Perfusion of AF647-fibrinogen over washed fluorescein isothiocyanate (FITC)-fibrin clots resulted in an intense red layer around, but not within, the original FITC-fibrin. Similarly, introduction of plasma/AF647-fibrinogen generated substantial red fibrin masses that did not penetrate the original green clots, demonstrating that fibrin cannot be re-clotted with fibrinogen. Overall, thrombin within fibrin is non-elutable, easily accessed by peptides, slowly accessed by average-sized proteins (heparin/AT), and not accessible to fresh fibrinogen.</pubmed_abstract><journal>Biophysical journal</journal><pubmed_title>Investigating thrombin-loaded fibrin in whole blood clot microfluidic assay via fluorogenic peptide.</pubmed_title><pmcid>PMC9989883</pmcid><funding_grant_id>U01-HL-131053</funding_grant_id><funding_grant_id>R01 HL103419</funding_grant_id><funding_grant_id>U01 HL131053</funding_grant_id><funding_grant_id>T32-HL-007971</funding_grant_id><funding_grant_id>R01-HL-103419</funding_grant_id><funding_grant_id>T32 HL007971</funding_grant_id><pubmed_authors>Crossen J</pubmed_authors><pubmed_authors>Shankar KN</pubmed_authors><pubmed_authors>Diamond SL</pubmed_authors></additional><is_claimable>false</is_claimable><name>Investigating thrombin-loaded fibrin in whole blood clot microfluidic assay via fluorogenic peptide.</name><description>During clotting under flow, thrombin rapidly generates fibrin, whereas fibrin potently sequesters thrombin. This co-regulation was studied using microfluidic whole blood clotting on collagen/tissue factor, followed by buffer wash, and a start/stop cycling flow assay using the thrombin fluorogenic substrate, Boc-Val-Pro-Arg-AMC. After 3 min of clotting (100 s&lt;sup>-1&lt;/sup>) and 5 min of buffer wash, non-elutable thrombin activity was easily detected during cycles of flow cessation. Non-elutable thrombin was similarly detected in plasma clots or arterial whole blood clots (1000 s&lt;sup>-1&lt;/sup>). This thrombin activity was ablated by Phe-Pro-Arg-chloromethylketone (PPACK), apixaban, or Gly-Pro-Arg-Pro to inhibit fibrin. Reaction-diffusion simulations predicted 108 nM thrombin within the clot. Heparin addition to the start/stop assay had little effect on fibrin-bound thrombin, whereas addition of heparin-antithrombin (AT) required over 6 min to inhibit the thrombin, indicating a substantial diffusion limitation. In contrast, heparin-AT rapidly inhibited thrombin within microfluidic plasma clots, indicating marked differences in fibrin structure and functionality between plasma clots and whole blood clots. Addition of GPVI-Fab to blood before venous or arterial clotting (200 or 1000 s&lt;sup>-1&lt;/sup>) markedly reduced fibrin-bound thrombin, whereas GPVI-Fab addition after 90 s of clotting had no effect. Perfusion of AF647-fibrinogen over washed fluorescein isothiocyanate (FITC)-fibrin clots resulted in an intense red layer around, but not within, the original FITC-fibrin. Similarly, introduction of plasma/AF647-fibrinogen generated substantial red fibrin masses that did not penetrate the original green clots, demonstrating that fibrin cannot be re-clotted with fibrinogen. Overall, thrombin within fibrin is non-elutable, easily accessed by peptides, slowly accessed by average-sized proteins (heparin/AT), and not accessible to fresh fibrinogen.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2026-06-17T06:34:11.631Z</modification><creation>2025-04-05T23:10:57.062Z</creation></dates><accession>S-EPMC9989883</accession><cross_references><pubmed>36635963</pubmed><doi>10.1016/j.bpj.2023.01.008</doi></cross_references></HashMap>